Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01223404 · ClinicalTrials.gov registry record · NA
Nicotinic Modulation of the Default Network
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT01223404 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 21 participants.
The verdict
NCT01223404, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and schizophrenia, display abnormal regulation of the so-called default network of resting brain function that maintains internally directed thought when the mind is free to wander. There is indication that nicotine may improve attention by aiding the deactivation of the default network, and this mechanism may be of therapeutic benefit for the above disease states. The current project aims at providing a proof of concept by demonstrating that nicotinic drugs modulate default network function. The nicotinic agonist nicotine is hypothesized to improve attention by facilitating the down-regulation of default network activity, and the nicotinic antagonist mecamylamine is hypothesized to impair attention by impeding the down-regulation of default network activity during attentional task performance.
Interventions
- DRUG Placebo
- DRUG Nicotine
- DRUG Mecamylamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01223404
The ClinicalTrials.gov registry entry for NCT01223404 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01223404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01223404 about?
NCT01223404 is a clinical study titled "Nicotinic Modulation of the Default Network". Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and schizophrenia, display abnormal regulation of the so-called default network of resting brain function that maintains internally directed thought when the mind is free to wander. There is indication that nicotin...
What is the current status of trial NCT01223404?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2010-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01223404?
The interventions under investigation include: Placebo (DRUG), Nicotine (DRUG), Mecamylamine (DRUG).
Who is sponsoring clinical trial NCT01223404?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.